EGFR and neoplasm: Positive PD-L1 staining (P = .0426) and tumor mutational burden elevation (P = .0264), as well as KRAS mutations, were more frequent in the LITT + ICB group, while tumors were more frequently driven by EGFR or ALK in the LITT-only group (P = .0021).